Drug Profile
Asunercept - Apogenix
Alternative Names: APG-101; Apocept; Asinercept; CAN-008Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Apogenix
- Developer Apogenix; CANbridge Pharmaceuticals; University Hospital Heidelberg
- Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Glioblastoma
- No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Solid tumours; Stroke
Most Recent Events
- 18 Aug 2023 Apogenix terminates the phase III trial in COVID-2019 infections (Adjunctive treatment) in Austria, France, Georgia, Germany, India, Italy, Poland, South Africa, Spain due to lack of patients (IV) (NCT05639192)
- 28 Mar 2023 NMPA grants Class 1 New Drug Designation to asunercept, prior to March 2023
- 28 Mar 2023 CANbridge Pharmaceuticals completes enrolment in phase-II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in China (IV) (NCT05447195)